Statin Therapy Among Bariatric Patients: The Impact on Metabolic Outcomes and Diabetes Status

Abstract

Introduction Statin therapy is associated with an increased risk of developing diabetes. Among bariatric patients, the influence of this therapy on various metabolic outcomes, such as diabetes status and its remission, is largely unknown.

Methods This was a retrospective study of 1710 patients who underwent bariatric surgery at our hospital between January/2010 and June/2017. We compared patients with and without statin therapy at baseline, 12 and 24 months after surgery regarding statin use and its impact on several clinical and analytical parameters. Multiple linear regression was performed, adjusting differences for age, sex, surgery type, antidiabetic drugs at baseline, hypertension at baseline, LDL cholesterol ˃ 130 mg/dL, weight variation one year after surgery, and age of obesity onset.

Results The overall prevalence of statin use was 20.2% before, 13.6% 12 months after surgery, and 15.0% 24 months after surgery. There was a larger reduction in fasting glucose and HbA1c at 12 and 24 months after surgery among statin-treated patients, with the opposite trend for weight reduction and BMI. Statin-treated patients with diabetes had lower diabetes remission rates (45.3 vs 68.5%) 12 months after surgery, with the highest reduction in HbA1c (1.3±1.3 vs −1.1±1.2%; p=0.042), fasting glucose (−40.8±48.8 vs −30.9±41.6 mg/dL; p=0.028), and insulin (−21.7±28.2 vs −13.4±14.2 mIU/L; p=0.039). The proportion of new-onset cases of diabetes was equal between statin-treated vs non-treated individuals at 12 months (1.9%) and 24 months (1.0%) after surgery.

Conclusion Bariatric surgery seems to lead to diabetes remission more frequently in patients not treated with statins. A larger reduction was observed in fasting glucose and HbA1c among statin-treated patients. Statin did not contribute to an increased proportion of new-onset diabetes after surgery.

Key words

Bariatric surgery - Statins - Diabetes Mellitus

Publication History

Received: 13 August 2021
Received: 26 December 2021

Accepted: 07 January 2022

Article published online:
23 March 2022

• References

• 1 Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Statins: Pros and cons. Med Clin 2018; 150: 398-402
• 2 Adhyaru BB, Jacobson TA. Safety and efficacy of statin therapy. Nat Rev Cardiol 2018; 15: 757-769
• 3 Casula M, Mozzanica F, Scotti L. et al. Statin use and risk of new-onset diabetes: A meta-analysis of observational studies. Nutr Metab Cardiovasc Dis 2017; 27: 396-406
• 4 Thakker D, Nair S, Pagada A. et al. Statin use and the risk of developing diabetes: A network meta-analysis. Pharmacoepidemiol Drug Saf 2016; 25: 1131-1149
• 5 Rahal AJ, ElMallah AI, Poushuju RJ. et al. Do statins really cause diabetes? A meta-analysis of major randomized controlled clinical trials. Saudi Med J 2016; 37: 1051-1060
• 6 Galicia-Garcia U, Jebari S, Larrea-Sebal A. et al. Statin treatment-induced development of type 2 diabetes: From clinical evidence to mechanistic insights. International J Mol Sci 2020; 21: 4725
• 7 Nguyen NT, Varela JE. Bariatric surgery for obesity and metabolic disorders: State of the art. Nat Rev Gastroenterol Hepatol 2017; 14: 160-169
• 8 Taylor BA, Ng J, Stone A. et al. Effects of statin therapy on weight loss and diabetes in bariatric patients. Surg Obes Relat Dis 2017; 13: 674-680
• 9 Perna M, Baker M, Byrne TK. et al. Statins and the bariatric patient: characterization and perioperative effects of statin therapy in the gastric bypass patient. Am Surg 2011; 77: 44-47
• 10 Mendonça F, Silva MM, Salazar D. et al. Bariatric surgery impact on cardiovascular risk factors: Is age a factor to consider?. Obes Facts 2021; 14: 72-77
• 11 Sattar NA, Ginsberg H, Ray K. et al. The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. Atheroscler Suppl 2014; 15: 1-15
• 12 Ko MJ, Jo AJ, Kim YJ. et al. Time- and dose-dependent association of statin use with risk of clinically relevant new-onset diabetes mellitus in primary prevention: A nationwide observational cohort study. J Am Heart Assoc 2019; 8: e011320